Celldex Therapeutics (CLDX) closed at $28.97 on October 22, 2026, down 1.4% from the previous close, on volume of 782,084 shares (30-day average 1,936,673).
Data as of October 22, 2026.
22-Oct-2026
Morgan Stanley Keeps Their Buy Rating on Celldex (CLDX)
TipRanks (Tue, 20-Oct 8:35 AM ET)
PRNewswire (Mon, 12-Oct 9:10 AM ET)
Celldex Highlights Phase 3 Barzolvolimab Data With Complete Response Near 54% at 24 Weeks in CSU
Market Chameleon (Tue, 22-Sep 7:36 AM ET)
Celldex reports Phase 3 barzolvolimab CSU wins as complete response rates approach 54% by Week 24
Market Chameleon (Tue, 22-Sep 3:28 AM ET)
Globe Newswire (Tue, 22-Sep 6:58 AM ET)
Celldex to Present at Upcoming Investor Conference
Globe Newswire (Tue, 8-Sep 4:01 PM ET)
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
Globe Newswire (Thu, 6-Aug 4:01 PM ET)
Market Chameleon (Wed, 25-Feb 6:17 AM ET)
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Celldex Therapeutics trades on the NASDAQ stock market under the symbol CLDX.
As of October 22, 2026, CLDX stock price declined to $28.97 with 782,084 million shares trading.
CLDX has a beta of 1.24, meaning it tends to be more sensitive to market movements. CLDX has a correlation of 0.08 to the broad based SPY ETF.
CLDX has a market cap of $2.27 billion. This is considered a Mid Cap stock.
Last quarter Celldex Therapeutics reported $22,000 in Revenue and -$.94 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.12.
In the last 3 years, CLDX traded as high as $53.18 and as low as $14.40.
The top ETF exchange traded funds that CLDX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
CLDX has underperformed the market in the last year with a price return of +3.8% while the SPY ETF gained +14.9%. CLDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.8% and -4.8%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
CLDX support price is $28.44 and resistance is $30.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLDX shares will trade within this expected range on the day.
